The Refiners Took the Money and Ran: Oil Down, Refining Up, Health Care Pays the Bill

Market regime

The 10/13 tape did not rotate so much as hand the baton to a single block. The average US stock fell -0.30% on a narrow negative skew (1,397 advancers / 1,595 decliners) and 126 names lost 5% or more against 28 winners - the second consecutive session of fat left-tail damage after 10/12's 191 decliners down 5%+. Average RSI has stalled in the 46 area for three sessions. What differs from the past two weeks is where the losses landed. Ten days ago the damage was in rate-sensitives and small caps; on 10/13 it showed up in Health Care (-2.42%, the worst sector) and in the semiconductor complex (AMAT -6.7%, FLEX -5.4%, CDNS -4.1%, each down 12%+ on the week), while Energy rose +1.36%. This is not a de-risking tape. It is a re-ranking tape.

Mega forces

1. Refining economics have decoupled from crude. WTI fell -2.5% into the session yet Integrated Oil & Gas gained +6.9% on the week, with 100% of the 22-name theme above its 50-day - the only theme in the book at full participation. Money is buying downstream and integrated, not the commodity: VLO +4.7%, PSX +4.0%, MPC +4.0%, BP +3.9%, several at 52-week highs with RSI 75-80. The driver is the crack spread and product margins, not the barrel, and reported DPA support for a Texas refinery build adds a policy tailwind to capacity.

2. Rate-sensitive equity duration is being repriced lower, and the index is paying for it. Long Treasuries are -3.1% over 1M and -6.1% over 3M, the dollar is +3.8% in a month, and 20Y Treasuries are -8.4% on the year. That is the mechanism behind the specific wreckage: Utilities show just 6 uptrends versus 57 downtrends, Real Estate 28 vs 94, and 83% of Financials sit below their 50-day. Financials' 42% uptrend reading is a legacy of the curve, not of current price - a distinction worth making before buying bank beta.

3. Single-name events are draining the highest-beta cohort. Health Care's -2.4% was JNJ -5.7% on 2.4x volume after weak medical-device sales, compounded by negative Merck pipeline commentary. But the contagion is the story: SMMT -9.4%, BNTX -7.1%, VKTX -6.0%, SRPT -5.3% - Neurology & Rare Diseases is -4.4% on the week with average RSI 33. Meanwhile 10-year yields fell 5bp to 4.63% and the 10Y-2Y spread steepened to +0.51, so this is positioning, not a fundamental deterioration in biotech.

What's working

Energy first, and not the whole sector: large-cap refiners and integrateds are up ~5% on the week on 250M+ liquidity, versus a Resources complex where gold and silver miners fell -5.1% with RSI 40 as the dollar strengthened. The defensive middle is quietly building - Consumer Staples +2.7% on the week with 44% of names above the 50-day, versus Financials' 16% - and pharma-adjacent services are intact (CROs +5.5% 1M, 80% above the 50-day) even as clinical-stage biotech is destroyed. Avoid the exact inverse: SPACs (-21% 1M) are now a funding-regime casualty rather than a niche, and semiconductor capital equipment is -10.7% on the week despite a +8.4% 1M, meaning the month's gains are being given back fast.

Strategy

Own cash-generating, low-duration cyclicals and let the crowd pay for hope. Practically: refiners and integrateds on pullbacks toward the 50-day, not at RSI 78; Consumer Staples and health-care services (CROs, life-science tools) as the funded side of the barbell; and treat semiconductor capex as a source of funds until its 30% above-50-day reading stops eroding. Size positions smaller in the meantime: with 126 names down 5%+ in a single session and only 84 active breakouts market-wide against 49 support breaks, the tape is punishing idiosyncratic risk faster than it is rewarding it.